Data / Drug companies / Bryant Ranch Prepack
Bryant Ranch Prepack: 1,138 products in the FDA NDC directory, labeler code 63629
Bryant Ranch Prepack (labeler code 63629) lists 1,138 products in the FDA National Drug Code Directory, covering 363 finished drugs by generic name. By type: 1,117 prescription drugs, 21 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 3, 2024.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 63629
- Products in commercial distribution
- 1,138
- Packages
- 2,157
- Finished drugs by generic name
- 363
- Prescription products
- 1,117
- Over the counter products
- 21
- Controlled substance products
- Schedule II 89, Schedule III 21, Schedule IV 65, Schedule V 8
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 15
- Earliest marketing start
- June 3, 1975
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 1,051 | 92.4% |
| Other unapproved drugs | 52 | 4.6% |
| Authorized generics (NDA) | 17 | 1.5% |
| Over the counter monograph drugs | 12 | 1.1% |
| New drug applications (NDA) | 6 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 1,117 | 98.2% |
| Over the counter drugs | 21 | 1.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 414 | 36.4% |
| Capsule | 156 | 13.7% |
| Tablet, film coated | 142 | 12.5% |
| Cream | 61 | 5.4% |
| Ointment | 41 | 3.6% |
| Tablet, film coated, extended release | 37 | 3.3% |
| Tablet, extended release | 32 | 2.8% |
| Capsule, extended release | 30 | 2.6% |
| Solution | 26 | 2.3% |
| Gel | 17 | 1.5% |
| Kit | 15 | 1.3% |
| Tablet, coated | 13 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dapagliflozin | 63629-3253 | Tablet, film coated | Authorized generics (NDA) | January 3, 2024 |
| Darunavir 600 and 800 mg | 63629-5686 | Tablet | Generic drugs (ANDA) | November 29, 2023 |
| Brimonidine | 63629-9616 | Gel | Generic drugs (ANDA) | January 1, 2023 |
| Sulfasalazine | 63629-9715 | Tablet | Generic drugs (ANDA) | December 15, 2022 |
| Lidocaine and prilocaine | 63629-9604 | Cream | Generic drugs (ANDA) | December 5, 2022 |
| Carbidopa and Levodopa | 63629-4134 | Tablet | Generic drugs (ANDA) | November 28, 2022 |
| Hydroxychloroquine sulfate | 63629-4465 | Tablet | Generic drugs (ANDA) | October 24, 2022 |
| Naproxen and esomeprazole magnesium | 63629-4873 | Tablet, delayed release | Generic drugs (ANDA) | October 6, 2022 |
| Tri-Estarylla | 63629-2350 | Kit | Generic drugs (ANDA) | September 1, 2022 |
| Carbamazepine | 63629-5914 | Tablet, extended release | Generic drugs (ANDA) | August 20, 2022 |
| Chlorthalidone | 63629-4446 | Tablet | Generic drugs (ANDA) | August 5, 2022 |
| Adapalene and benzoyl peroxide | 63629-9322 | Gel | Generic drugs (ANDA) | June 2, 2022 |
| Betamethasone dipropionate | 63629-9324 | Ointment | Generic drugs (ANDA) | May 20, 2022 |
| Betamethasone dipropionate | 63629-9323 | Ointment | Generic drugs (ANDA) | May 20, 2022 |
| Diclofenac potassium | 63629-4871 | Capsule, liquid filled | Generic drugs (ANDA) | March 24, 2022 |
| Tobramycin and dexamethasone | 63629-9572 | Suspension/ drops | Generic drugs (ANDA) | March 17, 2022 |
| Tobramycin and dexamethasone | 63629-9571 | Suspension/ drops | Generic drugs (ANDA) | March 17, 2022 |
| Tobramycin and dexamethasone | 63629-9570 | Suspension/ drops | Generic drugs (ANDA) | March 17, 2022 |
| Methimazole | 63629-9251 | Tablet | Generic drugs (ANDA) | February 28, 2022 |
| Methimazole | 63629-9250 | Tablet | Generic drugs (ANDA) | February 28, 2022 |
| Methimazole | 63629-9249 | Tablet | Generic drugs (ANDA) | February 28, 2022 |
| Nebivolol | 63629-9589 | Tablet | Generic drugs (ANDA) | February 14, 2022 |
| Sodium Sulfacetamide | 63629-9264 | Liquid | Other unapproved drugs | January 15, 2022 |
| Sodium Sulfacetamide | 63629-9263 | Liquid | Other unapproved drugs | January 15, 2022 |
| Sodium Sulfacetamide | 63629-9262 | Liquid | Other unapproved drugs | January 15, 2022 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.